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Mutations in ROGDI Cause Kohlschu¨tter-To¨nz Syndrome
Anna Schossig,1,3,14 Nicole I. Wolf,2,4,14 Christine Fischer,3 Maria Fischer,5 Gernot Stocker,5
Stephan Pabinger,5 Andreas Dander,5 Bernhard Steiner,6 Otmar To¨nz,6 Dieter Kotzot,1 Edda Haberlandt,7
Albert Amberger,1 Barbara Burwinkel,8,9 Katharina Wimmer,1 Christine Fauth,1
Caspar Grond-Ginsbach,10 Martin J. Koch,11 Annette Deichmann,12 Christof von Kalle,12
Claus R. Bartram,3 Alfried Kohlschu¨tter,13 Zlatko Trajanoski,5 and Johannes Zschocke1,3,*
Kohlschu¨tter-To¨nz syndrome (KTS) is an autosomal-recessive disease characterized by the combination of epilepsy, psychomotor regres-
sion, and amelogenesis imperfecta. The molecular basis has not yet been elucidated. Here, we report that KTS is caused by mutations in
ROGDI. Using a combination of autozygosity mapping and exome sequencing, we identified a homozygous frameshift deletion,
c.229_230del (p.Leu77Alafs*64), in ROGDI in two affected individuals from a consanguineous family. Molecular studies in two addi-
tional KTS-affected individuals from two unrelated Austrian and Swiss families revealed homozygosity for nonsense mutation
c.286C>T (p.Gln96*) and compound heterozygosity for the splice-site mutations c.531þ5G>C and c.532-2A>T in ROGDI, respectively.
The latter mutation was also found to be heterozygous in the mother of the Swiss affected individual in whom KTS was reported for
the first time in 1974. ROGDI is highly expressed throughout the brain and other organs, but its function is largely unknown. Possible
interactions with DISC1, a protein involved in diverse cytoskeletal functions, have been suggested. Our finding that ROGDImutations
cause KTS indicates that the protein product of this gene plays an important role in neuronal development as well as amelogenesis.Kohlschu¨tter-To¨nz syndrome (KTS, MIM 226750) is a rare
genetic disorder characterized by the combination of
epilepsy, psychomotor delay and regression, and amelogen-
esis imperfecta. So far, 24 individuals with the clinical diag-
nosis of KTS have been reported.1–9 Pedigrees suggest an
autosomal-recessive mode of inheritance, but genetic
heterogeneity cannot be excluded. The molecular basis of
KTS has not yet been elucidated. The most striking feature
is global enamel deficiency (amelogenesis imperfecta) of
the hypoplastic or hypocalcified type; this deficiency affects
primary as well as permanent teeth right from the moment
of eruption. The enamel is very thin, rough, prone todisinte-
gration, and stained in various shades of brown. Onset of
epilepsy usually occurs in the first year of life; seizures are
difficult to treat or might be refractory to therapy. Affected
children show severe psychomotor delay or regression,
which might be present after birth but more frequently
develops after the onset of seizures. Both gross and fine
motor skills are usually impaired, and intellectual disability
might be severe. The natural course is variable; several
affected individuals developed spastic tetraplegia, and
somedied in childhood.There arenoconsistentdysmorphic
features or metabolic abnormalities, although nonspecific
facial anomalieshavebeenreported insomeaffected individ-
uals. Cranial imaging frequently shows mild brain atrophy.
In order to identify the genetic basis of KTS, we investi-
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Clinical features of the affected individuals are summa-
rized in Table 1. Family A is a consanguineous Moroccan
family with two affected children (A-IV:3 and A-IV:4;
Figure 1);9 the parents are first cousins. Initial development
of the affected boy (A-IV:3) appeared normal, but treat-
ment-resistant epilepsy started when he was 4 months
old and led to loss of fixation and global developmental
delay. The affected younger sister (A-IV:4) showed psycho-
motor delay from birth onward. Epileptic seizures, which
were difficult to treat, started when she was 12 months
old. The first teeth in both children erupted when they
were 13 and 14 months old, respectively; from the begin-
ning, their teeth were lusterless and had a brownish dis-
coloration. Family B has been reported previously;8 the
parents of the affected boy (B-II:1) are not knowingly
related but come from neighboring villages in East Tyrol
(Austria). Epilepsy started when the boy was 5 months
old but later improved; there were no seizures after 7 years
of age, and medication was discontinued when he was
15 years old. Primary and permanent teeth were yellow,
hypoplastic, and crowded. Family C has one affected girl
(C-XI:2) who has not yet been reported. Left-sided hemi-
convulsive seizures started when she was 6 months old
and were initially difficult to treat, but when she was
6 years old, anticonvulsive treatment could be discontin-
ued. Primary and secondary dentition showed enamel, Austria; 2Department of Child Neurology, VU University Medical Center,
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Table 1. Clinical Features of KTS and ROGDI Genotypes in the Affected Individuals
A-IV:3 A-IV:4 B-II:1 C-XI:2











Age at time of last
evaluation
12 years 9 years 18 years 9 years
Growth parameters mild microcephaly normal normal normal

















35 single words and
sentences with two words;
social and friendly behavior
competent to talk in
short and simple sentences
Age of walking
without support
4.5 years 2.2 years 2.5 years 2 years























seizures (1–5 per day);
only seizures with
fever since start of
levetiracetam at
3.5 years of age
mostly myoclonic
seizures (1–5 per day);
only seizures with
fever since start of
levetiracetam
at 1.8 years of age
focal and generalized
seizures (1–5 per day);
seizure free since 7 years
of age and no medication





since 6 years of age
Hearing normal normal normal normal
Vision loss of visual fixation
after onset of seizures
normal normal normal
Dentition eruption of first teeth
at 13 months of age;
discoloration from
the beginning
eruption of first teeth









The following abbreviation is used: EEG, electroencephalography.abnormalities typical of KTS (Figure 2). Genealogical
studies revealed that this girl is distantly related to the
mother of the affected individuals (C-IX:3) reported in
19741 via both the maternal line (six generations ago)
and the paternal line (nine generations ago). The parents
of individual C-XI:2 are also eighth cousins (see family C
in Figure 1).
In order to identify the candidate gene for KTS, we per-
formed linkage analysis and autozygosity mapping in
family A. Analyses of all families were carried out with
informed consent and were approved by the institutional
review board at Medical University Innsbruck. Affected
individuals, siblings, parents, and grandparents were in-
vestigated. We analyzed 250 ng of genomic DNA from
each individual on the SNP-based mapping-chip Gene-
Chip HumanMapping 10K Array (Affymetrix, Santa Clara,
CA, USA); we used the operating software (Affymetrix
GCOS 1.4) and genotyping-analysis software (Affymetrix
GTYP 4.0) according to the manufacturer’s instructions.
A multipoint LOD score was calculated with the software702 The American Journal of Human Genetics 90, 701–707, April 6, 2programs Allegro10 and ALOHOMORA.11 The haplotype
analysis and the LOD-score estimation based on the model
of autosomal-recessive inheritance showed four possible
linkage regions in chromosomal regions 3q13.31–q13.32,
11q24.1–q24.2, 16p13.3, and 17q25.1–q25.3 (Figure 3A).
LOD scores in these regions ranged between 1.05 and
2.06. The autozygous regions had a total size of 15.83 Mb
and contained 326 known protein-coding genes (see
Table S1).
Considering the large number of genes in the autozy-
gous regions, we decided to use whole-exome sequencing
(carried out by ServiceXS, Leiden, The Netherlands) for
the genetic analysis of one affected individual (A-IV:4)
from family A. Exome capturing was performed with the
Agilent SureSelect Human All Exon Kit (Agilent, Santa
Clara, CA), and the sample was sequenced on an Illumina
Genome Analyzer II platform (Illumina, San Diego, CA).
Data analysis was carried out with the SIMPLEX pipeline,
which uses the Burrows Wheeler Aligner12 to map the
reads to the human reference-genome sequence (USCS012
Figure 1. Pedigrees of Investigated Families
The pedigree for family A shows a consanguineous Moroccan family9 in which linkage analysis and exome sequencing were performed.
The pedigree for family B shows a Tyrolean family affected by KTS,8 and the parents are not knowingly related. The pedigree for family
C shows the newly diagnosed Swiss family (the parents are X:1 and X:2) and its relationship with the distantly related index family
reported in 1974 (parents IX-3 und IX-4).1 Note that the parents in the newly identified family are distantly related to each other,
but the affected child is compound heterozygous for two different mutations.hg19, February 2009, Genome Reference Consortium
GRCh37). For SNP and DIP (deletion-insertion polymor-
phism) calling, as well as for realignment around indels,
we applied the Genome Analysis Toolkit (GATK).13 Exon
boundaries were specified by the Consensus Coding
Sequence (CCDS).10 An exome coverage depth of 233
was achieved: 46% of exons showed high coverage
(R203), and around 10% of exons showed low coverage
(%53). Variant detection identified 20,454 SNPs as well
as 1,208 DIPs. We annotated all variants with additional
information by using GATK and ANNOVAR14 to facilitate
the identification of disease-causing mutations. Subse-
quently, we applied the auto_annovar functionality to
filter variants against dbSNP (build 132), the 1,000
Genomes Project (Nov 2010), and previously assigned
conservation scores (for filtering details, see Table S2). After
all filtering steps, only a single strong candidate gene,
ROGDI (rogdi homolog [Drosophila], RefSeq accession
number NM_024589.1) in chromosomal region 16p13.3,
remained in the autozygous regions of interest. In exon 4
of this gene, we found a homozygous frameshift deletion,
c.229_230del (p.Leu77Alafs*64), which is predicted to
disrupt the amino acid structure and cause a premature
stop codon (Figure 3B). The filtering algorithm also called
a missense variant, c.2273G>C (p.Cys758Ser), in EVPL
(envoplakin [MIM 601590]) in the linkage region ofThe Am17q25.1; this variant (rs142251448) was included in build
134/135 of dbSNP and had a heterozygote frequency of
0.3% in the North American population.
After completing exome sequencing, we found a PhD
thesis that reports the results of autozygosity mapping in
five families affected by KTS.15 That study identified 30
candidate genes, including ROGDI, but did not find any
linkage to chromosomal region 17q25.1. There is no
other report on a possible link between KTS and ROGDI
or EVPL. Also considering the expected severity of the
frameshift deletion found in family A, we focused our
subsequent studies on ROGDI (Ensembl accession number
ENSG00000067836). This gene stretches over 5.98 kb in
chromosomal region 16p13.3 and contains 11 exons, all
of which are coding. Bioinformatics analysis showed that
the transcript of ROGDI codes for 287 amino acids and
results in a molecular weight of 32 kDa (RefSeq accession
number NP_078865.1). There is only one known func-
tional transcript. Dye-terminator sequencing of all exons
and adjacent intron sequences of ROGDI (NM_024589.1)
(ABI Prism 7000 sequence detection system, Applied Bio-
systems, Carlsbad, CA; primer sequences are available in
Table S3) confirmed the homozygous presence of the
mutation c.229_230del in both affected siblings of family
A (Figure 3C). As expected, both parents were found to
be heterozygous. Sequence analysis in family B revealederican Journal of Human Genetics 90, 701–707, April 6, 2012 703
Figure 2. Dental Phenotype in the So Far Unreported Individual
C-XI:2
Tooth discoloration due to global enamel defect (amelogenesis im-
perfecta).a homozygous nonsense mutation, c.286C>T, in exon 5 of
ROGDI in affected individual B-II:1 (Figure 3D). This muta-
tion is predicted to change a CAG triplet that codes for
glutamine into a TAG stop codon, denoted p.Gln96*.
Both parents in the family were heterozygous for this
mutation. In family C, two heterozygous splice-site muta-Figure 3. Linkage and Genomic Sequence Analyses
(A) Linkage analysis in family A revealed four autozygous regions in
(B) Exome sequencing in family A revealed a homozygous 2 bp dele
(C–F) Identification of mutations by Sanger sequencing. Homozygo
nonsense mutation c.286C>T (D) is present in family B, and hetero
are present in family C.
704 The American Journal of Human Genetics 90, 701–707, April 6, 2tions, c.531þ5G>C and c.532-2A>T, in intron 7 of ROGDI
were identified in affected individual C-XI:2 (Figures 3E
and 3F). In silico analysis indicated that both mutations
destroy the respective splice donor and acceptor sites of
intron 7 (Alamut [Interactive Biosoftware, Rouen, France],
data not shown). The mother (C-X:2) was found to be
heterozygous for c.532-2A>T, and the father (C-X:1) was
found to be heterozygous for c.531þ5G>C, confirming
compound heterozygosity in the affected child. The unaf-
fected sister (C-XI:1) was found to be heterozygous for
c.531þ5G>C. Finally, we acquired archival DNA from
the unaffected mother (C-IX:3) and four healthy siblings
(C-X:3, C-X:8, C-X:10, and C-X:13) of the original family
reported by Kohlschu¨tter et al.1 (family C in Figure 1);
none of these individuals have epilepsy and all have
normal intelligence and normal teeth with intact enamel.
The affected family members as well as the father of that
family are deceased, and their DNA samples are not avail-
able. The mother and all investigated siblings are heterozy-
gous for splice-site mutation c.532-2A>T, which is also
found in the mother of affected individual C-XI:2. It can
be assumed that the mothers from both family branches
have a common ancestor who lived in the Swiss valley of
Scha¨chental in the 18th century and who was a carrier
for this mutation (family C in Figure 1).chromosomes 3, 11, 16, and 17.
tion, c.229_230del, in exon 4 of ROGDI.
us deletion c.229_230del (C) is present in family A, homozygous




Figure 4. cDNA Analyses
(A) RT-PCR analysis of ROGDI in family C. Note the absence of the wild-type amplicon as well as the presence of two aberrant bands in
affected individual C-XI:2. One of the aberrant bands is approximately 100 bp shorter than the wild-type band and is also found in the
father (C-X:1) and sister (C-XI:1), who are both heterozygous for c.531þ5G>C. The other aberrant band is weak, approximately 80 bp
larger than the wild-type band, and is also observed in the mother (C-X:2), who is heterozygous for c.532-2A>T.
(B) RT-qPCR analysis of ROGDI in affected individuals, healthy family members, and controls shows markedly reduced mRNA transcript
in affected individual B-II:1. Heterozygosity for c.532-2A>T in C-X:2 is associated with a cDNA reduction of approximately 50%, most
likely reflecting nonsense-mediated decay of that allele. In contrast, heterozygosity for c.531þ5G>C is not associated with the loss of
cDNA in C-X:1 and C-XI:1. The fact that affected individual C-XI:2 has half normal cDNA reflects the combination of both alleles.
The error bars represent means and standard deviations of three independence measurements of the probands and four controls.
(C) cDNA sequence analysis of the RT-PCR product of exons 6–9 in individual C-X:1, heterozygous for c.531þ5G>C, shows skipping of
in-frame ROGDI exon 7.All mutations identified were frameshift, nonsense, or
splice-site mutations that are expected to either cause
premature mRNA degradation by nonsense-mediated
decay or dramatically alter protein structure and conse-
quently cause complete loss of protein function. They are
not listed in publicly available genome-variant databases
and are absent from the 1,000 Genomes Project. In order
to assess the functional effects of the different mutations,
we obtained fresh peripheral-blood samples from the
affected individuals in families B and C. Peripheral-blood
mononuclear cells (PBMC) were isolated from blood
samples and cultivated in the presence of phytohemagglu-
tinin (Quantum PBL by PAA Laboratories GmbH, Pasch-
ing, Austria) for three days. Thereafter, RNA was isolated,
and cDNA synthesis was performed by standard methods.
RT-PCR amplification spanning exons 6–9 of the tran-
scripts in affected individual C-XI:2 (primer sequences
are available as Table S4) showed that the wild-type
amplicon (386 bp) was absent but that a strong shorter
band (approximately 290 bp) and a weak band somewhat
larger than the wild-type band were present (Figure 4A).
The other family members showed the wild-type ampli-
con, but the father and sister (both heterozygous forThe Amc.531þ5G>C) also showed the shorter band, and the
mother (heterozygous for c.532-2A>T) also showed the
weak larger band. Dye-terminator sequencing of these
products revealed that the short band reflects an in-frame
deletion of exon 7 caused by mutation c.531þ5G>C
(Figure 4C). The other amplicon associated with mutation
c.532-2A>T was detectable as background sequencing
trace in the mother and the affected child. The aberrant
transcript is a result of the use of an intron 7 cryptic splice
acceptor site that leads to the inclusion of an additional
83 nucleotides before exon 8 (data not shown). The pre-
dicted effect is the inclusion of two abnormal amino acids
followed by a stop codon. cDNA sequence analysis was not
performed in affected individual B-II:1, who is homozy-
gous for the nonsense mutation c.286C>T, which is not
expected to affect splicing.
We quantified the expression of ROGDI with real time
PCR by using specific primers spanning exons 3–4 (primer
sequences are available in Table S4) and Maxima SYBR
Green/ROX qPCR Master Mix (Fermentas) in an Applied
Biosystems Prism 7000 sequence detection system. PCR
reaction was carried out under standard conditions.
The cycle threshold (Ct) values were calculated witherican Journal of Human Genetics 90, 701–707, April 6, 2012 705
sequence-detection system (SDS) software v1.2 (Applied
Biosystems). We quantified relative gene expression with
the comparative DDCt method by using HPRT1 (RefSeq
accession number NM_000194.2) as a reference gene.
These analyses showed that the amount of ROGDI cDNA
was markedly reduced to 10.6% (much lower than the
mean of the four controls) in affected individual B-II:1
(Figure 4B). The amount of cDNA in affected individual
C-XI:2 was 43.6%, similar to the value of 46.9% in her
mother (C-X:2). The amount of ROGDI cDNA in the father
and sister was in the normal range (86.6% and 100.2%,
respectively).
In summary, the cDNA analyses confirm that the muta-
tions in affected individuals B-II:1 and C-XI:2 severely
disrupt the normal ROGDI transcript. Mutation
c.531þ5G>C causes skipping of in-frame exon 7 but
does not lead to a translational frameshift and is not asso-
ciated with nonsense-mediated decay. In contrast, muta-
tion c.532-2A>T triggers the use of a cryptic intronic splice
acceptor site, explaining both a larger size of the cDNA
amplicon and nonsense-mediated decay. The latter effect
was also observed for nonsense mutation c.286C>T.
Thus, the mutations in all three KTS-affected families are
expected to be severe (null) mutations that are likely to
cause complete loss of ROGDI function.
The exact function of the protein encoded by ROGDI
is unknown. Using ANNIE,16 sequence-structure analysis
showed neither relevant features (e.g., transmembrane
regions or signal peptides) nor relevant protein domains.
Protein prediction methods17 indicate that ROGDI is a
globular protein and that the secondary structure consists
of 45% helixmotifs, 37% loop structures, and 17% strands.
The gene is highly conserved and has orthologs in many
species, including Drosophila melanogaster. It shows partic-
ularly high expression levels in various human brain
regions,18 in line with the CNS phenotype of KTS. A
Drosophila mutant of this gene showed a possible defi-
ciency in olfactory memory.19 Yeast two-hybrid screens20
suggested a possible interaction between ROGDI and
DISC1 (MIM 605210), a protein implicated in the develop-
ment of schizophrenia and involved in processes of cyto-
skeletal stability and organization, neuronal migration,
intracellular transport, and cell division.21 There are no
published studies that examined the role of ROGDI in
tooth development and amelogenesis. Our own data
provide robust information on the clinical effects of the
loss of ROGDI function in humans and provide interesting
perspectives for research into the molecular causes of
epilepsy and other conditions.
In conclusion, we report that KTS is caused by putative
loss-of-function mutations in ROGDI. All mutations
identified are predicted to be severe (null) mutations that
are likely to cause complete loss of protein function.
Heterozygosity for ROGDI-null mutations does not appear
to have any adverse effects. It is possible that individuals
with homozygosity or compound heterozygosity for
hypomorphic missense mutations in ROGDI could present706 The American Journal of Human Genetics 90, 701–707, April 6, 2with isolated epilepsy independently from minor enamel
defects or vice versa. Assessing potential genotype-pheno-
type correlations will require molecular studies on addi-
tional affected individuals. Although we found ROGDI
mutations in all KTS-affected individuals investigated so
far, we cannot rule out genetic heterogeneity. Future
work will hopefully elucidate the exact function of ROGDI
in neuronal development and amelogenesis.Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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